pathology-2018-scientifictracks

8 / 21

Pathology 2018 Research & Reviews: Journal of Medical and Health Sciences
ISSN: 2319-9865 Page 33
October 08-09, 2018
Edinburgh, Scotland
17th International Conference on
Pathology & Cancer
Epidemiology
B reast cancer is curable if detected early, as well proven
by the UK National Breast Cancer Screening Programme.
Developed countries of the world have clear breast cancer
screening guidelines emphasizing self-breast awareness,
clinical breast examination and mammogram algorithms.
But developing countries in the world the situation is not very
encouraging. Many cancer detection camps are happening, but
they cannot reach larger population. Hence when developed
countries significantly reduced their breast cancer mortality
rate in countries like India the mortality rate due to breast
cancer is around 50% (as per latest IARC report). Hence author
thought of using smartphone technology for early detection
of breast cancer through the BREXA mobile app. The app has
the following features like: To score for risk of getting breast
cancer; monthly reminders and video assistance for self-breast
check; information about the different tests used in breast
cancer diagnosis; once the woman crosses 40 years of age, the
app automatically reminds and assist in booking for screening
mammogramevery year; the results of the testswill be available
within the app; if the app detects high risk women, such women
are given further guidance by expert panel of doctors; users
can also book appointments with doctors and laboratories
through the app and avail discounts on mammography; Even
after diagnosis, guidance and information is available in the
app, making it a comprehensive cancer solution. BREXA is now
available in English, Malayalam, Arabic and Hindi. BREXA is
completely free and can be downloaded from Google play or
App store. It is designed as if a doctor companion is always
with the woman giving guidance. With effective use of BREXA
app, women over world can be saved from breast cancer
deaths, which are caused due to late detection. The main aim
of this mission is: no more family without a mother due to
breast cancer and save mothers and save the world.
Recent Publications
1. Sreekala Sreehari and Balaji Balasubramanian; GIST
or Not - A Unique Case of Low Grade Endometrial
Stromal Sarcoma with Review of Literature;
Journal of Cytology & Histology 2016; J Cytol
Histol 7: 414. doi:10.4172/2157-7099.1000414]
2. Kutty SA, Sreehari S; Co-occurrence of intracranial
Rosai-Dorfman disease and Langerhans histiocytosis
of the skull: case report and review of literature. Turk
Neurosurg. 2015;25(3):496-9. doi: 10.5137/1019-
5149.JTN.10542-14.1. Review. PMID:26037195
3. Zuhara Shemin, Sreekala Sreehari, Annie Jojo; Renal
cell carcinoma with Xp11.2 translocation/TFE3 gene
fusions-experience from a tertiary care hospital in
Kerala, India; Journal of Histology & Histopathology
2015; ISSN 2055-091X | Volume 2 | Article 6; http://
pdf 2 doi: 10.7243/2055-091X-2-6
4. Kumar A, Sreehari S, Velayudhan K, Biswas L, Babu
R, Ahmed S, Sharma N, Kurupath VP, Jojo A, Dinesh
KR, Karim S, Biswas R; Autochthonous blastomycosis
of the adrenal: first case report from Asia. Am J
Trop Med Hyg. 2014 Apr;90(4):735-9. doi: 10.4269/
ajtmh.13-0444. Epub 2014 Feb 3. PMID: 24493676
5. Anil Kumar V, Francis E, Sreehari S, Raj B; Tricuspid
valve mycetoma in an infant successfully treated by
excision and complex tricuspid valve repair followed
by fluconazole therapy. Surg Infect (Larchmt). 2014
Apr;15(2):134-40. doi: 10.1089/sur.2013.007. Epub
2013 Oct 12. PMID: 24116856
Biography
Sreekala Sreehari is currently the Lead of Centralized Histopathology Lab-
oratory at NMC Royal Hospital, Khalifa City. Currently she is the Country
Advisor to UAE of Royal College of Pathologists, UK. She is an active mem-
ber of Pathological Society of Great Britain and Ireland, Europeon Society of
Pathology and IAP. She is recently selected as an External Peer Assessor to
UKAS (United Kingdom Accreditation Services ISO 15189:2012). With more
than 10 years of international experience, she is an expert diagnostician.
Her key areas of interests include Oncopathology related to breast, colon,
head, neck, male and female genital systems and a core member of NMC
Oncocare tumor boards. She is playing a key role in National Cancer Screen-
ing Programmes related to breast, colon and cervix in the region. She has
authored and co-authored several articles, done audits and been part of sev-
eral projects. Early cancer detection, digital pathology, environmental safety,
technology developments in cancer care and laboratory quality standards
are her main areas of interest.
Preventing breast cancer deaths by early detection: an
innovative mobile app companion for every women
Sreekala Sreehari
NMC Healthcare, UAE
Sreekala Sreehari, RRJMHS 2018
Volume: 7